

#4
5/21/03
82

10/03/00
Jc828 U.S. PTO



TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
5711-D1-01-MG

In Re Application Of: **DANETTE ANDREA DUDLEY, ET AL.**

Serial No.

Filing Date

Examiner

Group Art Unit

Title: **QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND THROMBIN**

Address to:

**Assistant Commissioner for Patents
Washington, D.C. 20231**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

Express Mail No. EF378134428US

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
5711-D1-01-MG

In Re Application: **DANETTE ANDREA DUDLEY, ET AL.**

10/03/006
10/04/02

Serial No.

Filing Date

Examiner

Group Art Unit

QUINOXALINONES AS SERINE PROTEASE INHIBITORS SUCH AS FACTOR XA AND

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **23-0455** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: **January 4, 2002**

Heidi M. Berven

Registration No. 48,951

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-5218

Fax (734) 622-1553

CC:

4

Sheet 1 of 2

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 5711-D1-01-MG	SERIAL NO.
	APPLICANT DANETTE A. DUDLEY, ET AL.	
	FILING DATE	GROUP

 JCE28 U.S. PTO
 10/038006
 01/04/02

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4 0 8 2 7 3 5	4/4/78	Jones et al.	260	112.5 R	
		4 0 8 2 7 3 6	4/4/78	Jones et al.	260	112.5 R	
		4 8 7 0 1 7 5	9/26/89	Suzuki et al.	544	354	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		1 2 5 4 3 4 8	11.10.89	Japan				x
		9 7 0 7 1 1 6	27.02.97	WO				x
		63 1 4 5 2 7 2	17.06.88	Japan				x
		9 8 0 1 4 2 8	15.01.98	WO				x
		9 8 0 1 4 2 8	15.01.98	WO revised version				x
		9 7 4 8 7 0 6	24.12.97	WO				x
		9 8 1 3 3 6 8	02.04.98	WO				x

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

		PCT International Search Report, PCT/US98/26704
		Lappato et al., "X-ray structure of anitstasin at 1.9 Å resolution and its modeled complex with blood coagulation factor Xa", <u>The EMBO Journal</u> , Vol. 16, No. 17, 5151-5161, 1987
		Mellott et al., "Enhancement of Recombinant Tissue Plasminogen Activator-induced Reperfusion by Recombinant Tick Anticoagulant Peptide, A Selective Factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <u>Fibrinolysis</u> , 7, 1993, 195-202
		Lynch et al., "Primary Prevention of Coronary Arterial Thrombosis with the Factor Xa Inhibitor rTAP in a Canine Electrolytic Injury Model", <u>Thrombosis and Haemostasis</u> , 74 (2) 640-5, 1995
		Schaffer et al., "Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide", <u>Circulation</u> , 1991, 84:1741-1748
		Fioravanti, et al., "Antithrombotic Activity of Recombinant Tick Anticoagulant Peptide and Heparin in a Rabbit Model of Venous Thrombosis", <u>Thrombosis Research</u> , 71, 317-324, 1993

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 5711-D1-01-MG	SERIAL NO.
	APPLICANT DANETTE A. DUDLEY, ET AL.	
	FILING DATE	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

		Wong et al., "Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis", <u>Thrombosis Research</u> , Vol. 83, No. 2, 117-126, 1996
		Edmunds and Rapundalo, "Annual Reports in Medicinal Chemistry", 31, 51-60, 1996
		Kunitada and Nagahura, "Factor Xa Inhibitors", <u>Current Pharmaceutical Design</u> , 1996, 2, 531-542
		Matuszczak and Mereiter, "Syntheses in the series of pyrazolyl-substituted quinoxalines", <u>Heterocycles</u> , Vol. 45, No. 12, 1997, 2449-2462
		Leardini et al., "Peroxydicarbonate-Mediated Oxidation of N-(ortho-Aryloxyphenyl) and N-(ortho-Arylamino-phenyl)aldimines", <u>Tetrahedron</u> , Vol. 51, No. 44, 12143-12158, 1995
		Awad and Hassan, "Studies in Vilsmeier-Haack Reaction. Application to Quinoxalineones", <u>Collect. Czech. Chem. Commun.</u> , Vol. 55, 1990, 2715-2721
		Otomasu et al., "Quinoxaline 1,2-Dihydroimidazo[1,2-a]-quinoxaline 1,2-Dihydro-3H-pyrimido[1,2-a]quinoxaline", <u>Yakugaku Zasshi</u> , 90 (11), 1391-1395, 1970
		Seth et al., "Studies in Antiamoebic Agents: Syntheses of Substituted Indophenazines, Azaindophenazines & Azaquinoxalines", <u>Indian Journal of Chemistry</u> , Vol. 12, 1974, 124-128
		Sparatore et al., "Quinolizidine Derivatives as Potential Antitumoral Agents", <u>Il Farmaco</u> , 44 (10), 945-950, 1989
		Hahn et al., "Effect of Mepyramine and Spasmolytic Agents on Guinea-Pig Anaphylaxis with Special Reference to the Protracted Shock", <u>Arch. Int. Pharmacodyn.</u> , 199, 108-121, 1972
		Chemical Abstracts, Vol. 111, No. 9, 1989, abstract 78027u
		Morrow and Regan, "Some Unusual Oxidation Reactions of 1,3-Diaryl-3,4-dihydro-7-methoxy-2(1H)-quinoxalineones", <u>J. Org. Chem.</u> , Vol. 36, No. 1, 1971, 27-31
		Katoh et al., "Structural Analysis of N-(-phenylalkyl)substituted quinoxaline-2(1H)-ones and -thiones", <u>Heterocycles</u> , Vol. 44, No. 1, 1997, 357-366
		Kurasawa et al., "Revised Structure for the Production from the Reaction of 3-Hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline with Nitrous Acid", <u>Chem. Pharm. Bull.</u> , 32 (10), 4140-4143, 1984

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.